Investigating how certain cell receptors contribute to pain in oral cancer
Official title: Endosomal mechanisms signaling oral cancer pain
Funded at New York University · NIH-10786660 · Data updated 2026-11-12
This study is looking into how certain cell receptors might be causing pain for people with oral cancer, and by gathering information from patients about their pain and tumor samples, researchers hope to better understand how this pain happens and find ways to help.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $4,820,611 |
| NIH project number | 1RM1DE033491-01 |
| Project ID | NIH-10786660 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with oral cancer who are experiencing pain.
✕Less likely to help
Patients without a diagnosis of oral cancer or those not experiencing pain may not benefit from this research.
What this research studies
This research explores the role of specific receptors in cells that may be responsible for pain experienced by patients with oral cancer. It focuses on how these receptors, located in endosomes, send signals that can lead to chronic pain. By collecting data from oral cancer patients, including their pain experiences and tumor samples, the study aims to understand the mechanisms behind pain signaling. The research employs a reverse translational approach, which means it uses findings from patients to inform laboratory studies and vice versa.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that alleviate pain for patients suffering from oral cancer.
How similar studies have gone: Other research has shown promise in understanding pain mechanisms through similar receptor signaling approaches, indicating potential for success in this area.
Where this research is happening
-
New York University
New York, United States Active
Researchers
- Principal investigator: Schmidt, Brian L — New York University
- Study coordinator: Schmidt, Brian L
Related research
Other NIH-funded projects on the same topics.
-
Endosomal signaling and cancer pain control in oral cancer
A study to understand how signals inside nerve cells and supportive cells contribute to pain in people with oral cancer.
-
Truncated TrkB and Oral Cancer Pain in Head and Neck Cancer
This project looks at a specific brain receptor told to influence pain in people with oral cancer to find new ways to reduce pain without heavy opioids.
-
Understanding how mouth cancer proteases drive pain in patients
This NIH grant looks at how enzymes in oral cancer tumors may cause pain, aiming to connect specific proteases with how patients feel pain.
-
Blocking HB-EGF and trigeminal EGFR to reduce oral cancer pain and opioid tolerance
Blocking HB-EGF and EGFR signals in trigeminal nerve cells to try to reduce severe mouth cancer pain and slow opioid tolerance for people with oral cancer.
-
Continuous flow production of antibody-loaded nanoparticles for non-opioid oral cancer pain relief
A non-opioid approach using antibody-packed nanoparticles is being developed to relieve oral cancer pain and improve quality of life.
-
Investigating a specific protein's role in pain from oral cancer
This study is looking at how a protein called TrkBT1 affects pain in people with head and neck cancer, with the goal of finding better ways to manage that pain without relying too much on opioids.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.